PTC Therapeutics board approves $500 million stock buyback

PTC Therapeutics, Inc. (NASDAQ: PTCT) disclosed on November 3, 2026, that its board of directors had authorized a share repurchase program allowing the company to buy back up to $500 million of its outstanding common stock, subject to market conditions.¹

The company said repurchases could occur at various times at management's discretion, using methods such as open-market trades including pre-set trading plans, privately negotiated deals, accelerated share repurchases, and other transaction types permitted under securities law.¹

CEO Matthew B. Klein, M.D., characterized the move as reflecting confidence in the company, saying the buyback program reflects the company's conviction in its strength and its near- and long-term growth prospects.¹ He added that the company is investing in PTC at a time when its shares present what it considers a compelling opportunity, while still preserving financial flexibility to fund existing programs and pursue potential business development deals it views as value creating.¹

Per the filing, details on any actual repurchases will appear in PTC's future quarterly and annual reports filed with the SEC.¹

The disclosure was made in a Form 8-K under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Information), with the underlying press release furnished as Exhibit 99.1. PTC said the press release announcing the board's authorization of the repurchase program was furnished as an exhibit to the report and incorporated by reference into the Regulation FD disclosure item.¹ The filing was signed by Pierre Gravier, Chief Financial Officer, dated November 3, 2026.